Inclusion Criteria:  Group 1: Interstitial Lung Disease and Other Parenchymal Lung Diseases  Known or suspected interstitial lung disease regardless of radiographic pattern Interstitial lung disease due to alternative autoimmune etiology Sarcoidosis Organizing pneumonia Hypersensitivity pneumonitis absent known or suspected trigger Primary pulmonary lymphoma Other idiopathic pulmonary conditions at discretion of study team  Group 2: Refractory Airway Symptoms  Chronic cough despite treatment trials with albuterol, proton-pump inhibitors and anti-histamine and intranasal corticosteroids Persistent bronchial hyperreactivity (defined as positive response to methacholine challenge on spirometry or subjective worsening after exposure to airway irritants such as tobacco, pollution, etc) or persistent asthma symptoms despite trial of inhaled corticosteroid and long acting bronchodilator Unexplained persistent bronchial wall thickening on CT imaging Recurrent or chronic bronchiolitis (including but not limited to chronic bronchiolitis, obliterative bronchiolitis, lymphocytic bronchiolitis, constrictive bronchiolitis associated with bronchiolar destruction, and panbronchiolitis) Bronchiectasis Lymphocytic alveolitis on bronchoalveolar lavage absent hypersensitivity pneumonitis with known trigger or HIV Recurrent bacterial pneumonia (greater than 2 episodes in 1 year, confirmed by focal consolidative opacity on chest imaging and requiring antibiotic therapy)  Group 3: Other  •Select patients outside the protocol testing schema who have one of the above lung diseases and are found to have Sjogren's syndrome through the course of their normal clinical care will be invited to participate in the data collection portion of the study for analyzing longitudinal outcomes.  Exclusion Criteria:  Patients with interstitial lung disease due to a known or suspected trigger such as drug-induced (including but not limited to nitrofurantoin, amiodarone, methotrexate and other chemotherapies), inorganic dust exposure (including but not limited to asbestos, silica, hard metals, coal dust) or organic exposure (including but not limited to birds, hay, mold). Patients who have taken a muscarinic antagonist or agonists within 7 days of planned testing Patients who are unable to consent for themselves